Results 201 to 210 of about 220,644 (260)

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang   +5 more
wiley   +1 more source

Activation of mitophagy antagonizes high uric acid-induced hepatic lipid accumulation. [PDF]

open access: yesJ Biol Chem
Chen J   +18 more
europepmc   +1 more source

Sono‐Vasomics With Super‐Resolution Contrast‐Enhanced Ultrasound (SR‐CEUS) for Characterization of Focal Liver Lesions: A Case Report

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
ABSTRACT Accurate differentiation between benign and malignant focal liver lesions (FLLs) remains a major diagnostic challenge. Vasomics, an emerging discipline, classifies vascular phenotypes into anatomical, biomechanical, biochemical, pathophysiological, and composite categories. Sono‐Vasomics, the ultrasound‐based subset, leverages super‐resolution
Yijie Qiu   +5 more
wiley   +1 more source

Machine learning‐based predictive models versus traditional risk scores in hemodialysis patients with comorbid urolithiasis

open access: yesPrecision Medical Sciences, EarlyView.
Machine learning‐based predictive models outperform traditional risk scores in hemodialysis patients with comorbid urolithiasis by capturing nonlinear, dialysis‐specific interactions. These approaches enable more accurate prediction of stone recurrence, sepsis, hospitalization, and mortality, supporting personalized risk stratification and precision ...
Dipal Chaulagain   +4 more
wiley   +1 more source

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

open access: yesRheumatology &Autoimmunity, EarlyView.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li   +5 more
wiley   +1 more source

Uric acid as a potential biomarker for cardiomyopathy in dystrophinopathy. [PDF]

open access: yesAnn Med
Li Z   +8 more
europepmc   +1 more source

SERS‐Based Nano‐ and Microsystems Toward Biomedical Applications

open access: yesSmall, EarlyView.
This review provides a current overview of nano‐ and microscale SERS‐based devices, encompassing all aspects from material design to practical applications. We highlight controlled SERS‐active architectures, including patterned substrates, nanorods, microspheres, micromotors, and microneedles, as well as combinations of these microfluidic systems.
Gohar Soufi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy